Author

D. Schwefel

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 3 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Assay:proteomics· 3 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 1 Organism:non-human primate· 1 Research Focus:protein folding & dynamics· 1 Organism:rat· 1

Frequent Co-Authors

C. M. T. Spahn· 3 shared T. Mielke· 3 shared A. Graziadei· 2 shared A. Rojas-Fernandez· 2 shared C. Gotthold· 2 shared J. Burger· 2 shared J. Rappsilber· 2 shared P. Chana-Cuevas· 2 shared

Activity by Year

2020-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersBiochemistry

C. M. T. Spahn

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Specific proteolysis mediated by a p97-directed proteolysis-targeting chimera (PROTAC)

C. Salinas-Rebolledo, J. Blesa, G. Valenzuela-Nieto, D. Schwefel, N. Lopez Gonzalez del Rey, M. Mendez-Ruette, J. Burkhalter, L. F. Batiz, R. Jara, J. A. Obeso, P. Chana-Cuevas, G. P. Sapkota, A. Rojas-Fernandez

This paper describes the engineering of a PROTAC that uses p97-directed proteolysis to achieve specific substrate degradation without relying on E3 ubiquitin ligases.

bioRxiv · Mar 8, 2024Biochemistry

An alpaca-derived nanobody neutralizes the SARS-CoV-2 omicron variant

N. Modhiran, S. M. Lauer, A. A. Amarilla, P. Hewins, S. I. L. van den Broek, Y. S. Low, N. Thakur, B. Liang, G. V. Nieto, J. Jung, D. Paramitha, A. Isaacs, J. de Sng, D. Song, J. Jorgensen, , D. Watterson

This paper identifies a nanobody that effectively neutralizes the SARS-CoV-2 Omicron variants BA.1 and BA.2, showing high affinity and pre-clinical promise.

bioRxiv · Dec 27, 2022 · PreprintMicrobiology

Structure and mechanism of a novel cytomegaloviral DCAF mediating interferon antagonism

V. T. K. Le-Trilling, S. Banchenko, D. Paydar, P. M. Leipe, L. Binting, S. Lauer, A. Graziadei, C. Gotthold, J. Burger, T. Bracht, B. Sitek, R. J. Lebbink, A. Malyshkina, T. Mielke, J. Rappsilber, , D. Schwefel

This study identifies E27 as a viral protein that targets STAT2 for degradation via CRL4 ubiquitin ligases, revealing its structural mechanism of interferon antagonism.

bioRxiv · May 5, 2022Biochemistry

Structural insights into Cullin4-RING ubiquitin ligase remodelling by Vpr from simian immunodeficiency viruses

S. Banchenko, F. Krupp, C. Gotthold, J. Buerger, A. Graziadei, F. O' Reilly, L. Sinn, O. Ruda, J. Rappsilber, C. M. T. Spahn, T. Mielke, I. A. Taylor, D. Schwefel

This paper investigates how SIVmus Vpr interacts with CRL4DCAF1 to ubiquitylate SAMHD1, revealing structural and mechanistic insights into viral counteraction of host restriction factors.

bioRxiv · Dec 31, 2020Biochemistry